Neoleukin Therapeutics, Inc. — FY2021 Form 10-K
Filing identity: The supplied filing is for Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), not Neurogene Inc. It covers the fiscal year ended December 31, 2021; it is an annual report, not a standalone Q4 report. Financial amounts below are in U.S. dollars.
Business context and reporting period
Neoleukin is a clinical-stage biopharmaceutical company using computational de novo protein design to develop immunotherapies for cancer, inflammation and autoimmunity. Its lead candidate, NL-201, is a designed IL-2/IL-15 agonist intended to stimulate immune activity while avoiding binding to the IL-2 receptor alpha subunit, CD25. NL-201 was in a Phase 1 trial for advanced solid tumors. The company had no approved products and no product revenue.
Key financial metrics
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | Not applicable |
| Research and development expense | $39.2 million | $24.3 million | Up 61% |
| General and administrative expense | $21.5 million | $17.2 million | Up 25% |
| Net loss | $60.7 million | $33.3 million | Loss widened by $27.4 million |
| Net loss per share, basic and diluted | $1.10 | $0.64 | Loss per share increased |
| Cash used in operating activities | $47.6 million | $24.6 million | Use increased by $23.0 million |
| Cash and cash equivalents at year-end | $142.5 million | $192.6 million | Down $50.1 million |
| Working capital at year-end | $135.4 million | Not stated in the supplied text | Not clear |
| Total liabilities at year-end | $20.4 million | $19.3 million | Up $1.1 million |
The company reported no meaningful operating margin because it had no product revenue and operated at a loss. Liabilities were primarily lease obligations and accounts payable/accruals; the filing does not report borrowings or other funded debt. Operating lease obligations totaled $19.2 million undiscounted, with finance lease obligations of $0.1 million.
Material changes versus the prior comparable period
- R&D expense rose mainly because of NL-201 clinical-trial activity, personnel costs, advancement of other platform programs and the Seattle headquarters/laboratory build-out.
- Operating cash use nearly doubled, reflecting higher operating expenses and facility costs. Year-end cash declined by $50.1 million.
- FY2020 included a $7.8 million gain on the sale of Aquinox Canada; there was no corresponding gain in FY2021. This prior-year item partly explains the larger reported net loss in FY2021.
- FY2020 financing provided $77.1 million, largely from a public offering. FY2021 financing provided $0.7 million, primarily from option exercises and the employee stock purchase plan.
- Stock-based compensation increased to $11.6 million from $5.6 million.
Guidance, outlook, risks and unusual items
- Management estimated that available cash and cash equivalents would fund planned operations into the second half of 2023, based on its current operating plan. It cautioned that actual cash needs could differ and additional capital may be needed sooner.
- Management planned to report interim solid-tumor Phase 1 data in the second half of 2022, add a pembrolizumab combination arm to the ongoing trial, and start a Phase 1 trial in hematological malignancies in 2022. These are forward-looking plans, not results.
- On January 10, 2022, after the fiscal year-end, Neoleukin announced a clinical collaboration with Merck to evaluate NL-201 with KEYTRUDA (pembrolizumab).
- The principal risks include early-stage clinical and platform uncertainty; potential serious adverse events or immunogenicity; reliance on third-party trial and manufacturing providers; competition; intellectual-property and license risks; and the need for substantial additional capital. COVID-19 could disrupt trials, suppliers and operations.
- The company had a $40.0 million at-the-market equity sales agreement, but reported no sales under it through December 31, 2021. Issuing shares could dilute existing holders.
- The University of Washington license includes annual maintenance fees beginning in 2022, development and regulatory milestones of up to $0.9 million per distinct licensed product class, commercial milestones of up to $10.0 million per class, and low-single-digit royalties on qualifying net sales, as well as certain sublicense and transaction payments.
- Neoleukin reported no material legal proceedings. Its auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. The auditor did not attest to internal control effectiveness; management concluded controls were effective as of year-end.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Neoleukin Therapeutics, not Neurogene Inc.
- Review subsequent NL-201 clinical-trial disclosures, including safety, dose selection, enrollment and whether the stated 2022 development plans occurred.
- Track cash burn, cash runway and any subsequent financing or collaboration proceeds; the stated runway is management’s estimate.
- Assess the impact of the 12.7 million outstanding pre-funded warrants, stock options, equity-plan share reserves and potential ATM sales on fully diluted ownership.
- Review the University of Washington license terms and any future milestone, royalty, sublicense or termination disclosures.